Results 1 to 10 of about 1,130 (117)

Analysis of postmarketing neuropsychiatric adverse events of avapritinib based on the FDA adverse event reporting system [PDF]

Scientific Reports
Neuropsychiatric adverse events (AEs) significantly impact the quality of life of patients using avapritinib. However, the majority of current data comes from pre-marketing, with limited real-world studies.
Wei Mao, Junyan Jiang, Yanping Xia, Lin Zhang   +3 more
exaly   +3 more sources

Absolute Configuration and Chiroptical Properties of Flexible Drug Avapritinib [PDF]

Pharmaceuticals
Background/Objective: Avapritinib is an orally bioavailable tyrosine kinase inhibitor and was approved by the FDA in 2020 for gastrointestinal stromal tumor treatments.
, Bei-Bei Yang
exaly   +4 more sources

Avapritinib for targeting KIT D816V-mutated acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplant with extramedullary and central nervous system involvement [PDF]

Annals of Hematology
Relapse of acute myeloid leukemia with CBFB::MYH11 fusion and KIT D816V mutation after allogeneic hematopoietic stem cell transplantation is uncommon and often associated with aggressive extramedullary spread and poor outcomes, particularly when the ...
Marco Frigeni, Alessandra Algarotti, Silvia Salmoiraghi, Clara Belotti, Martina Milani, Chiara Pavoni, Orietta Spinelli, Irene Gotuzzo, Alessandro Rambaldi, Federico Lussana   +9 more
doaj   +2 more sources

Avapritinib in Advanced Gastrointestinal Stromal Tumor: Case Series and Review of the Literature From a Tertiary Care Center in India

Future Science OA, 2021
The therapeutic landscape in advanced gastrointestinal stromal tumor has evolved. Avapritinib and ripretinib have now been approved by the US FDA for platelet-derived growth factor alpha D842V-mutant and refractory gastrointestinal stromal tumor patients,
Shamim Ahmed Shamim, Sh Chandrashekhara, Rohit Reddy   +2 more
exaly   +3 more sources

Metadynamics reveals luteolin-mediated conformational stabilization against avapritinib-resistant PDGFRα D842V/G680R GIST [PDF]

Scientific Reports
Gastrointestinal stromal tumors (GISTs) driven by PDGFRα D842V mutations respond robustly to avapritinib, but acquired resistance through secondary mutations such as G680R creates steric hindrance that compromises drug binding.
Kaoutar El Khattabi, Jihane Akachar, Sanaa Lemriss, Rachid El Jaoudi, Fouad Zouaidia   +4 more
doaj   +2 more sources

Avapritinib in the treatment of systemic mastocytosis with associated acute myeloid leukemia after poor graft function following allogeneic hematopoietic stem cell transplantation: a case study and review of the literature [PDF]

Frontiers in Oncology
IntroductionThis case is reported due to its novelty in demonstrating the efficacy of avapritinib, a selective KIT inhibitor, in a rare systemic mastocytosis-associated acute myeloid leukemia (SM-AML) patient with non-D816V KIT mutations and RUNX1 ...
Ruihua Mi, Xiang Li, Lin Chen, Lin Wang, Yixuan Ma, Yuewen Fu, Xudong Wei   +6 more
doaj   +2 more sources

A comprehensive analysis of the adverse drug events of metastatic and unresectable gastrointestinal stromal tumor treatment options: avapritinib, imatinib, regorafenib, ripretinib, and sunitinib safety insights and implications [PDF]

Future Science OA
Background Treatments for metastatic, unresectable, or treatment-resistant gastrointestinal stromal tumors (GIST) include avapritinib, imatinib, regorafenib, ripretinib, and sunitinib.
Cameron M. Thompson, Michael B. Andrews, Douglas G. Adler   +2 more
doaj   +2 more sources

Anaphylaxis events in the PIONEER study of avapritinib in indolent systemic mastocytosis [PDF]

World Allergy Organization Journal
Background: Patients with indolent systemic mastocytosis (ISM), a clonal mast cell disease primarily driven by the KIT D816V mutation, often have lifelong debilitating symptoms.
Thanai Pongdee, MD, Mariana Castells, MD, PhD, Cem Akin, MD, Ingunn Dybedal, MD, PhD, Jason Gotlib, MD, Jens Peter Panse, MD, Ivan Alvarez-Twose, MD, PhD, Cristina Morales Cabeza, MD, Sonia Cerquozzi, MD, FRCPC, Peter Vadas, MD, Vidushi Swarup, MS, Pankit Vachhani, MD, Friederike Wortmann, MD, Cecilia Arana Yi, MD, Ilda Bidollari, MD, Kate Newberry, PhD, Daniel Shaheen, PharmD, Karin Hartmann, MD   +17 more
doaj   +2 more sources

Case Report: Refractory systemic nmastocytosis with AML1::ETO+ acute myeloid leukemia driven by rare KIT mutation: remarkable therapeutic efficacy of avapritinib [PDF]

Frontiers in Pediatrics
This article describes two pediatric SM with AML1::ETO+ AML patients induced by novel KIT exon11 mutations not previously documented in medical literature.
Song Xue, Man Chen, Hui-peng Sun, Xing-yu Cao   +3 more
doaj   +2 more sources

Successful treatment with avapritinib in patient with mucosal metastatic melanoma

Therapeutic Advances in Medical Oncology, 2020
Metastatic vulvar melanoma is a rare and aggressive disease and survival is usually poor. Vulvar melanomas harbor BRAF V600 mutations only infrequently; consequently, target therapy is a rare therapeutic option and immunotherapy usually has only a weak ...
Pier Francesco Ferrucci, Laura Pala, Fabio Conforti   +2 more
exaly   +2 more sources